188 related articles for article (PubMed ID: 26160006)
21. Prostatectomy pathology findings in an active surveillance population.
Ramirez-Backhaus M; Iborra I; Gomez-Ferrer A; Rubio-Briones J
Arch Esp Urol; 2014 Jun; 67(5):431-9. PubMed ID: 24914842
[TBL] [Abstract][Full Text] [Related]
22. Stricter Active Surveillance Criteria for Prostate Cancer do Not Result in Significantly Better Outcomes: A Comparison of Contemporary Protocols.
Komisarenko M; Timilshina N; Richard PO; Alibhai SM; Hamilton R; Kulkarni G; Zlotta A; Fleshner N; Finelli A
J Urol; 2016 Dec; 196(6):1645-1650. PubMed ID: 27350077
[TBL] [Abstract][Full Text] [Related]
23. International multicentre study examining selection criteria for active surveillance in men undergoing radical prostatectomy.
Wong LM; Neal DE; Johnston RB; Shah N; Sharma N; Warren AY; Hovens CM; Larry Goldenberg S; Gleave ME; Costello AJ; Corcoran NM
Br J Cancer; 2012 Oct; 107(9):1467-73. PubMed ID: 23037714
[TBL] [Abstract][Full Text] [Related]
24. Improving risk stratification in patients with prostate cancer managed by active surveillance: a nomogram predicting the risk of biopsy progression.
Iremashvili V; Burdick-Will J; Soloway MS
BJU Int; 2013 Jul; 112(1):39-44. PubMed ID: 23551868
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive report on prostate cancer misclassification by 16 currently used low-risk and active surveillance criteria.
Palisaar JR; Noldus J; Löppenberg B; von Bodman C; Sommerer F; Eggert T
BJU Int; 2012 Sep; 110(6 Pt B):E172-81. PubMed ID: 22314081
[TBL] [Abstract][Full Text] [Related]
26. Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy.
Kulkarni GS; Lockwood G; Evans A; Toi A; Trachtenberg J; Jewett MA; Finelli A; Fleshner NE
Cancer; 2007 Jun; 109(12):2432-8. PubMed ID: 17497649
[TBL] [Abstract][Full Text] [Related]
27. Feasibility for active surveillance in biopsy Gleason 3 + 4 prostate cancer: an Australian radical prostatectomy cohort.
Wong LM; Tang V; Peters J; Costello A; Corcoran N
BJU Int; 2016 Apr; 117 Suppl 4():82-7. PubMed ID: 27094971
[TBL] [Abstract][Full Text] [Related]
28. The novel nomogram of Gleason sum upgrade: possible application for the eligible criteria of low dose rate brachytherapy.
Budäus L; Graefen M; Salomon G; Isbarn H; Lughezzani G; Sun M; Chun FK; Schlomm T; Steuber T; Haese A; Koellermann J; Sauter G; Fisch M; Heinzer H; Huland H; Karakiewicz PI
Int J Urol; 2010 Oct; 17(10):862-8. PubMed ID: 20812920
[TBL] [Abstract][Full Text] [Related]
29. Follow-up in Active Surveillance for Prostate Cancer: Strict Protocol Adherence Remains Important for PRIAS-ineligible Patients.
Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
Eur Urol Oncol; 2019 Sep; 2(5):483-489. PubMed ID: 31411970
[TBL] [Abstract][Full Text] [Related]
30. Percentage of cancer involvement in positive cores can predict unfavorable disease in men with low-risk prostate cancer but eligible for the prostate cancer international: active surveillance criteria.
Russo GI; Cimino S; Castelli T; Favilla V; Urzì D; Veroux M; Madonia M; Morgia G
Urol Oncol; 2014 Apr; 32(3):291-6. PubMed ID: 24184119
[TBL] [Abstract][Full Text] [Related]
31. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors.
Kattan MW; Eastham JA; Wheeler TM; Maru N; Scardino PT; Erbersdobler A; Graefen M; Huland H; Koh H; Shariat S; Slawin KM; Ohori M
J Urol; 2003 Nov; 170(5):1792-7. PubMed ID: 14532778
[TBL] [Abstract][Full Text] [Related]
32. Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men.
Chun FK; Haese A; Ahyai SA; Walz J; Suardi N; Capitanio U; Graefen M; Erbersdobler A; Huland H; Karakiewicz PI
Cancer; 2008 Aug; 113(4):701-9. PubMed ID: 18553365
[TBL] [Abstract][Full Text] [Related]
33. Optimizing the clinical utility of PCA3 to diagnose prostate cancer in initial prostate biopsy.
Rubio-Briones J; Borque A; Esteban LM; Casanova J; Fernandez-Serra A; Rubio L; Casanova-Salas I; Sanz G; Domínguez-Escrig J; Collado A; Gómez-Ferrer A; Iborra I; Ramírez-Backhaus M; Martínez F; Calatrava A; Lopez-Guerrero JA
BMC Cancer; 2015 Sep; 15():633. PubMed ID: 26362197
[TBL] [Abstract][Full Text] [Related]
34. Magnetic Resonance Imaging Targeted Biopsy Improves Selection of Patients Considered for Active Surveillance for Clinically Low Risk Prostate Cancer Based on Systematic Biopsies.
Ouzzane A; Renard-Penna R; Marliere F; Mozer P; Olivier J; Barkatz J; Puech P; Villers A
J Urol; 2015 Aug; 194(2):350-6. PubMed ID: 25747105
[TBL] [Abstract][Full Text] [Related]
35. Spatial distribution of positive cores improves the selection of patients with low-risk prostate cancer as candidates for active surveillance.
Abdollah F; Suardi N; Capitanio U; Gallina A; Sun M; Villa L; Scattoni V; Bianchi M; Tutolo M; Fossati N; Karakiewicz P; Rigatti P; Montorsi F; Briganti A
BJU Int; 2013 Aug; 112(4):E234-42. PubMed ID: 23746297
[TBL] [Abstract][Full Text] [Related]
36. Does cumulative prostate cancer length (CCL) in prostate biopsies improve prediction of clinically insignificant cancer at radical prostatectomy in patients eligible for active surveillance?
Chen DJ; Falzarano SM; McKenney JK; Przybycin CG; Reynolds JP; Roma A; Jones JS; Stephenson A; Klein E; Magi-Galluzzi C
BJU Int; 2015 Aug; 116(2):220-9. PubMed ID: 25060664
[TBL] [Abstract][Full Text] [Related]
37. Genetic predisposition to early recurrence in clinically localized prostate cancer.
Borque Á; del Amo J; Esteban LM; Ars E; Hernández C; Planas J; Arruza A; Llarena R; Palou J; Herranz F; Raventós CX; Tejedor D; Artieda M; Simon L; Martínez A; Carceller E; Suárez M; Allué M; Sanz G; Morote J
BJU Int; 2013 Apr; 111(4):549-58. PubMed ID: 22759231
[TBL] [Abstract][Full Text] [Related]
38. Tumor lesion diameter on diffusion weighted magnetic resonance imaging could help predict insignificant prostate cancer in patients eligible for active surveillance: preliminary analysis.
Lee DH; Koo KC; Lee SH; Rha KH; Choi YD; Hong SJ; Chung BH
J Urol; 2013 Oct; 190(4):1213-7. PubMed ID: 23727188
[TBL] [Abstract][Full Text] [Related]
39. Magnetic resonance imaging does not improve the prediction of misclassification of prostate cancer patients eligible for active surveillance when the most stringent selection criteria are based on the saturation biopsy scheme.
Ploussard G; Xylinas E; Durand X; Ouzaïd I; Allory Y; Bouanane M; Abbou CC; Salomon L; de la Taille A
BJU Int; 2011 Aug; 108(4):513-7. PubMed ID: 21176083
[TBL] [Abstract][Full Text] [Related]
40. How Active is Active Surveillance? Intensity of Followup during Active Surveillance for Prostate Cancer in the United States.
Loeb S; Walter D; Curnyn C; Gold HT; Lepor H; Makarov DV
J Urol; 2016 Sep; 196(3):721-6. PubMed ID: 26946161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
